Last reviewed · How we verify
NCT04687813: FTP-198
Safety, Tolerability and Pharmacokinetics of FTP-198 Tablet in Healthy Chinese Volunteers
Phase 1 trial testing Placebo in Healthy in 31 participants. Completed in 18 March 2021.
26 February 2021
Quick facts
| Lead sponsor | Haisco Pharmaceutical Group Co., Ltd. |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | other |
| Enrollment | 31 |
| Start date | 23 December 2020 |
| Primary completion | 26 February 2021 |
| Estimated completion | 18 March 2021 |
| Sites | 1 location across China |
Drugs / interventions tested
- Placebo
Conditions studied
- Healthy — all drugs for Healthy →
Sponsor
Haisco Pharmaceutical Group Co., Ltd. — full company profile →
Who can join
Adults 18 to 55, any sex, with Healthy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a Phase I, single-dose escalation clinical trial for FTP-198 conducted in chinese healthy volunteers. The safety, tolerability, food-impact and pharmacokinetics of FTP-198 tablet in healthy volunteers will be evaluated using a randomized, double-blind, placebo-controlled trial design.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04687813
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Placebo
Trials testing the same drug.
- NCT04516603 — Influence of Fampridine on Working Memory in Healthy Subjects · Phase 2 · withdrawn
- NCT06974968 — Efficacy of iPSC-Derived Motor Neuron Cells (XS228) in Subacute Spinal Cord Injury: A Phase II Randomized Controlled Tri · Phase 2 · not yet recruiting
- NCT04100109 — Evaluating the Metabolic Effects of Polylactose: A Novel Prebiotic · NA · withdrawn
- NCT05931484 — Study to Evaluate the Safety, Tolerability, Efficacy, and PK of FHL-301 in Parkinson's Disease Patients. · Phase 2 · not yet recruiting
- NCT07430332 — GLP-1 RA for Stage 1 Type 1 Diabetes · Phase 2 · not yet recruiting
Other recruiting trials for Healthy
Currently open trials in the same condition.
- NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
- NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
- NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
- NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
- NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting
Other Haisco Pharmaceutical Group Co., Ltd. trials
Trials by the same sponsor.
- NCT07533786 — A Clinical Trial Evaluating the Efficacy and Safety of HSK55718 in Patients for Postoperative Pain Treatment in Abdomina · Phase 2 · not yet recruiting
- NCT07519070 — A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of HSK44 · Phase 3 · not yet recruiting
- NCT07503587 — Evaluating the Efficacy and Safety of of HSK44459 in People With Progressive Pulmonary Fibrosis · Phase 3 · not yet recruiting
- NCT07521345 — A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and the Food Effect of HSK55879 Tablets in Healt · Phase 1 · recruiting
- NCT07335055 — A Study for HSK47388 in Participants With Ulcerative Colitis · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04687813 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Haisco Pharmaceutical Group Co., Ltd.
- Last refreshed: 23 January 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04687813.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing